Skye Bioscience reported a Q4 net loss of USD 14.44 million, widening 48%, and R&D expenses of USD 11.47 million, up 47% mainly due to contracted manufacturing costs tied to anticipated Phase 2b supply and employee-related benefits. For FY 2025, net loss widened to USD 55.92 million and R&D expenses more than doubled to USD 42.36 million, driven primarily by contracted clinical study and manufacturing costs for nimacimab and increased discovery research and compensation. Cash, cash equivalents and short-term investments were USD 25.7 million at year-end, and Skye said this is expected to fund operations and key clinical milestones through Q4 2026, excluding the anticipated clinical cost of a proposed Phase 2b trial and additional manufacturing to supply such a study. Skye said it initiated the CBeyond Expansion Study (Part C) with 400 mg and 600 mg IV weekly nimacimab monotherapy cohorts versus placebo over 15 weeks, and expects topline data in Q4 2026. CEO Punit Dhillon said CBeyond showed a combination signal and clean safety with no drug-related CNS toxicity at the tested dose, and the next step is defining the peripheral exposure-response at higher doses to inform Phase 2b dose selection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603101601PRIMZONEFULLFEED9669409) on March 10, 2026, and is solely responsible for the information contained therein.